Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | President, R&D and Tech Ops | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 203,900 |
Reported balance
After 2026-09-04 transaction · row 1
1 source rowRow 1 · 2026-09-04 · Tax withholding · Disposed 21,423 · Balance 203,900 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 9, 2026 00:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 21,423 | $22.22 | $476,019.06 |
DisclosureSEC source: 0001193125-26-385536 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,900 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 948 | $17.03 | $16,144.44 |
DisclosureSEC source: 0001193125-26-106703 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,323 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 895 | $16.95 | $15,170.25 |
DisclosureSEC source: 0001193125-26-102703 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,271 F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 504 | $16.95 | $8,542.80 |
DisclosureSEC source: 0001193125-26-102703 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,166 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 767 | $16.20 | $12,425.40 |
DisclosureSEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,670 F3 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 3,718 | $16.20 | $60,231.60 |
DisclosureSEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,437 F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089425 · ownership.xml · derivative · entry 4 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026. F1 · derivative.exercise_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026. F1 · derivative.expiration_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 1,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-083671 · ownership.xml · derivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Stock · 1,875 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,582 | $18.42 | $84,400.44 |
DisclosureSEC source: 0001193125-25-288556 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,030 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-197425 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,612 F3 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board. Read SEC document |
| September 03, 2025 Filed Sep 6, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 93,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-197425 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,612 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 00:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-104397 · ownership.xml · derivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 16,644 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · derivative · entry 6 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 Underlying: Common Stock · 16,644 shares Expires 2035-03-10 F5 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 4 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,631 F4 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,539 | $100.13 | $254,230.07 |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,355 F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 924 | $100.13 | $92,520.12 |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,894 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 7,990 | $103.70 | $828,563.00 |
DisclosureSEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,318 F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 514 | $103.70 | $53,301.80 |
DisclosureSEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,308 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · derivative · entry 5 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036694 · ownership.xml · derivative · entry 4 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,704 | $101.34 | $172,683.36 |
DisclosureSEC source: 0000950170-25-035002 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,322 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 715 | $103.77 | $74,195.55 |
DisclosureSEC source: 0000950170-25-032759 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,026 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. F2 · balance_after: Amount of Securities Beneficially Owned includes 111 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Restricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-020193 · ownership.xml · derivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 3,500 shares Expires not disclosed F1 · derivative.exercise_price: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| November 18, 2024 Filed Nov 21, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,558 | $102.89 | $468,972.62 |
DisclosureSEC source: 0000950170-24-129454 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,630 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021. F2 · balance_after: Amount of Securities Beneficially Owned includes 47 shares purchased under the Company's registered Employee Stock Purchase Plan on August 30, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,182 | $164.64 | $359,244.48 |
DisclosureSEC source: 0000950170-24-077521 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,141 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 5 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 4 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F3 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F3 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F3 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-077521 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 909 | $123.14 | $111,934.26 |
DisclosureSEC source: 0000950170-24-029532 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,073 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 512 | $120.49 | $61,690.88 |
DisclosureSEC source: 0000950170-24-029532 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,982 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,728 | $125.32 | $216,552.96 |
DisclosureSEC source: 0000950170-24-027496 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,494 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026607 · ownership.xml · derivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-01 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026607 · ownership.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,222 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 778 | $126.19 | $98,175.82 |
DisclosureSEC source: 0000950170-24-026607 · ownership.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,222 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: Amount of Securities Beneficially Owned includes 249 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,508 | $82.98 | $374,073.84 |
DisclosureSEC source: 0001209191-23-056168 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,751 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021. F2 · balance_after: Amount of Securities Beneficially Owned includes 89 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2023. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 912 | $153.19 | $139,709.28 |
DisclosureSEC source: 0001209191-23-018021 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,170 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017407 · doc4.xml · derivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-03-06 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017407 · doc4.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,082 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,134 | $157.21 | $178,276.14 |
DisclosureSEC source: 0001209191-23-017407 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,582 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 522 | $147.57 | $77,031.54 |
DisclosureSEC source: 0001209191-23-016054 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,716 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: Amount of Securities Beneficially Owned includes 240 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| November 17, 2022 Filed Nov 22, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,211 | $108.52 | $456,977.72 |
DisclosureSEC source: 0001209191-22-058284 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,998 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021. F2 · balance_after: Amount of Securities Beneficially Owned includes 98 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017343 · doc4.xml · derivative · entry 3 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-03-07 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017343 · doc4.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,111 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,216 | $79.20 | $96,307.20 |
DisclosureSEC source: 0001209191-22-017343 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,111 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 572 | $75.05 | $42,928.60 |
DisclosureSEC source: 0001209191-22-014409 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,327 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: The amount of securities directly owned by the reporting person includes 221 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on February 28, 2022. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 3,780 | $79.33 | $299,867.40 |
DisclosureSEC source: 0001209191-21-066948 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,678 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.